Trial · NCT00502307
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Open Label Period (16 Weeks) | STARTED | Open-label Period: Tivozanib (AV-951) | 272 | |
| Open Label Period (16 Weeks) | STARTED | Double-blind Period: Tivozanib (AV-951) | 0 | |
| Open Label Period (16 Weeks) | STARTED | Double-blind Period: Placebo | 0 | |
| Open Label Period (16 Weeks) | COMPLETED | Open-label Period: Tivozanib (AV-951) | 196 | |
| Open Label Period (16 Weeks) | COMPLETED | Double-blind Period: Tivozanib (AV-951) | 0 | |
| Open Label Period (16 Weeks) | COMPLETED | Double-blind Period: Placebo | 0 | |
| Open Label Period (16 Weeks) | NOT COMPLETED | Open-label Period: Tivozanib (AV-951) | 76 | |
| Open Label Period (16 Weeks) | NOT COMPLETED | Double-blind Period: Tivozanib (AV-951) | 0 | |
| Open Label Period (16 Weeks) | NOT COMPLETED | Double-blind Period: Placebo | 0 | |
| Double-Blind Period (12 Weeks) | STARTED | Open-label Period: Tivozanib (AV-951) | 0 | |
| Double-Blind Period (12 Weeks) | STARTED | Double-blind Period: Tivozanib (AV-951) | 61 | |
| Double-Blind Period (12 Weeks) | STARTED | Double-blind Period: Placebo | 57 | |
| Double-Blind Period (12 Weeks) | COMPLETED | Open-label Period: Tivozanib (AV-951) | 0 | |
| Double-Blind Period (12 Weeks) | COMPLETED | Double-blind Period: Tivozanib (AV-951) | 35 | |
| Double-Blind Period (12 Weeks) | COMPLETED | Double-blind Period: Placebo | 48 | |
| Double-Blind Period (12 Weeks) | NOT COMPLETED | Open-label Period: Tivozanib (AV-951) | 0 | |
| Double-Blind Period (12 Weeks) | NOT COMPLETED | Double-blind Period: Tivozanib (AV-951) | 26 | |
| Double-Blind Period (12 Weeks) | NOT COMPLETED | Double-blind Period: Placebo | 9 | |
| Maintenance Period | STARTED | Open-label Period: Tivozanib (AV-951) | 148 | |
| Maintenance Period | STARTED | Double-blind Period: Tivozanib (AV-951) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00502307/flow